Saundersdjs,
Yes this line of thinking has also been pondered over (at least twice in the past!)...Bene's area of expertise is Manufacturing. They have no interest in sales, in running clinical trials. They do what they do, and they are the best at it. They take a small royalty and that's enough for them. Sure I cant speak on their behalf but from the people I have chatted to that have had dealings with them, that's the feeling and impression I get.
PAR have a wonderfully close relationship with Bene and there is mutual respect and a great partnership there. Paul has mentioned it a couple of times both directly and also on publicly available sources too (eg interviews/AGM etc).
MADE IN GERMANY, page-11
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $69.17M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.0¢ | $148.6K | 756.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 190014 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 42970 | 10 |
View Market Depth
| Last trade - 15.31pm 01/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |